FDA Grants Fast Track to Verastem's Lung Cancer Drug for Unmet KRAS G12D Need
VSTM is trading near its 52-week low of $3.575 (2.7% above the low).
Summary
Verastem Oncology received FDA Fast Track designation for its drug VS-7375, targeting KRAS G12D-mutated non-small cell lung cancer (NSCLC). This designation accelerates the development and review process for drugs addressing serious conditions with unmet medical needs. The news is particularly significant given the company's recent Q1 report, which disclosed substantial doubt about its ability to continue as a going concern. There are currently no FDA-approved therapies specifically for KRAS G12D mutations in cancer, highlighting the unmet need this drug aims to address. Future clinical trial data and subsequent regulatory milestones will be critical to watch.
At the time of this announcement, VSTM was trading at $3.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $318.1M. The 52-week trading range was $3.58 to $11.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.